ArticleDie Ophthalmologie2026
[Anterior segment changes in mucopolysaccharidoses].
Article in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimMucopolysaccharidoses (MPS) are rare lysosomal storage disorders in which the accumulation of undegraded glycosaminoglycans leads to progressive multiorgan and ocular changes. The anterior segment of the eye is particularly affected, with type-specific, distinct corneal and chamber angle alterations. The aim of this study was to characterize anterior segment changes in different MPS types based on structural and functional examinations using clinical and imaging parameters.
methodsIn a clinical cross-sectional study, patients with MPS (types I, II, III, IV, VI) were compared with an age-matched control group. Data collection included general ophthalmic and orthoptic examinations, slit-lamp findings, anterior segment Scheimpflug imaging with the Oculus Pentacam® HR, optical biometry using the IOLMaster 700 and the anterior segment module of the SPECTRALIS® OCT (AS-OCT) for chamber angle assessment.
resultsA total of 58 eyes from 29 MPS patients and 58 eyes from healthy controls were analyzed. The MPS group was predominantly male patients (72.4%), whereas the control group was predominantly female (65.5%). The median age was 21 years (interquartile range, IQR 14-32) and 23 years (IQR 13-34), respectively. Best-corrected visual acuity was significantly reduced in MPS patients (median: 0.3 logMAR vs. -0.1 logMAR; p < 0.001). Stromal corneal opacities were observed in 44.8% of MPS eyes, predominantly in types I, IV and VI. Intraocular pressure was elevated (median: 16 mm Hg vs. 12 mm Hg; p < 0,001) without glaucomatous visual field defects or optic nerve head changes. The anterior chamber depth was significantly reduced (median: 3.0 mm vs. 3.5 mm; p < 0.001), as were anterior chamber angle parameters (ACA/AOD; both p < 0.001), particularly in MPS types I, II and VI.
conclusionAnterior segment morphology in MPS patients shows distinct type-specific pathological changes. Pentacam, IOL Master, and AS-OCT are suitable tools for detecting structural changes. Structured ophthalmological examinations can detect typical alterations in patients with MPS and enable early identification of changes.
Indexed as
Identifiers
42766130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.